Ozempic Stomach Paralysis Lawsuit

Ozempic and GLP-1 weight-loss drug stomach paralysis (gastroparesis) lawsuit

Published: October 30, 2023 · Updated: June 18, 2026

▼ Allegations Only · No Settlement Yet

This page describes ongoing litigation and an investigation. The statements below are unproven allegations. No manufacturer has been found liable, no settlement has been finalized, and eligibility depends on the facts of each case. This page is informational and is not legal or medical advice. Do not stop taking any prescribed medication without consulting your doctor.

Status Active Litigation consolidated in federal MDL 3094 · E.D. Pennsylvania

Drugs Involved GLP-1 medications Ozempic · Wegovy · Mounjaro · Rybelsus · Trulicity · Saxenda

Alleged Injury Gastroparesis & GI injury stomach paralysis, severe vomiting, intestinal blockage

Estimated Payout Varies no settlement fund yet; depends on diagnosis and damages

What Is This About?

Did you take an injectable weight-loss drug such as Ozempic and later experience gastric problems such as gastroparesis (stomach paralysis), intestinal obstruction or blockage, or persistent vomiting, nausea, or diarrhea? Did you report these issues to a doctor or seek medical care? If so, you may be eligible to speak with counsel about your legal options.

A growing body of reports describes patients taking the weight-loss drug Ozempic, along with others such as Wegovy, Mounjaro, Rybelsus, Trulicity, and Saxenda, who experienced painful side effects consistent with a condition known as gastroparesis, or stomach paralysis. Families have filed lawsuits alleging that manufacturers failed to adequately warn patients of these risks.

If you or someone you know experienced adverse side effects, consult a medical professional. If you believe your symptoms are related to one of these medications, you may be entitled to compensation for your injuries.

Which Weight-Loss Medications Are in the Investigation?

• Ozempic
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist originally used to manage type 2 diabetes. Its active ingredient is semaglutide, which mimics the effects of GLP-1, a naturally occurring hormone that helps regulate blood sugar and appetite. By enhancing insulin production and reducing glucose release from the liver, Ozempic is designed to control blood sugar and aid weight loss in diabetic patients.

• Wegovy
Wegovy and Ozempic contain the same active compound, but Wegovy contains a much higher dose of semaglutide. It received FDA approval as a weight-loss medication in 2021, the first new weight-loss medication to gain approval in several years.

• Saxenda
Saxenda is a GLP-1 medication that delivers an active compound called liraglutide. Liraglutide was originally approved by the FDA in 2010 as an adjunct therapy to diet and exercise for the management of type 2 diabetes, sold under the brand name Victoza. Following clinical trial results, liraglutide sold as Saxenda gained approval in 2014 as a weight-loss medication for people with a BMI of 30 or higher, or 27 or higher with a related metabolic health condition.

• Rybelsus
Rybelsus is an oral medicine used as a first-line medication to improve blood sugar control in adults with type 2 diabetes. It works by mimicking the effects of GLP-1, which stimulates insulin secretion and lowers glucagon secretion from the liver.

• Mounjaro
Mounjaro, also known as tirzepatide, is an injection used to improve blood sugar in adults with type 2 diabetes. It may help the body regulate blood sugar levels and decrease the amount of food eaten.

• Trulicity
Trulicity (generic name dulaglutide) helps lower A1C levels in those with type 2 diabetes. It works by limiting how much sugar gets into the bloodstream, slowing digestion, and helping the pancreas release insulin in response to high blood sugar after eating.

How Is Gastroparesis Linked to These Drugs?

A problematic trend has been identified with the increasing popularity of these weight-loss drugs, including Ozempic. Reports have surfaced suggesting a possible link between Ozempic and similar medications and a condition known as gastroparesis, also known as stomach paralysis.

Gastroparesis is a disorder in which the stomach takes longer than usual to empty its contents into the small intestine. This can lead to uncomfortable symptoms such as nausea, vomiting, bloating, and a feeling of fullness. Severe cases may result in malnutrition and other complications. There is no known cure for the condition, though withdrawal of the medication may lessen symptoms in some patients.

Many patients are now coming forward and seeking accountability from the drug manufacturers, alleging they failed to properly warn patients of the inherent risks of taking these treatments. Manufacturers have a duty to keep consumers safe and to warn them of risks. Lawsuits allege that a failure to do so entitles injured patients to pursue compensation, which can be used to cover associated medical bills, pain and suffering, and lost wages from time missed at work while recovering.

Who May Qualify?

You may qualify to speak with counsel if you took a GLP-1 weight-loss or diabetes drug such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, or Saxenda and were later diagnosed with, or treated for:

• Gastroparesis (stomach paralysis)
• Severe, persistent vomiting
• Intestinal obstruction or blockage (ileus)
• Other serious gastrointestinal injuries requiring medical care

Eligibility depends on the drug used, your diagnosis, and the facts of your case. Helpful evidence includes prescription records, the names and dates of the medications you took, and medical records confirming your diagnosis.

What Is the Current Status of the Litigation?

Federal lawsuits over GLP-1 weight-loss and diabetes drugs have been consolidated into multidistrict litigation (MDL 3094) in the U.S. District Court for the Eastern District of Pennsylvania. The cases remain ongoing, no settlement fund has been approved, and no claim deadline tied to a settlement has been set. Statutes of limitations still apply and vary by state, so injured patients should consult an attorney as soon as possible.

Frequently Asked Questions

Which weight-loss drugs are part of the investigation?

The investigation focuses on GLP-1 receptor agonist medications used for weight loss or type 2 diabetes, including Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, and Saxenda. These drugs contain active ingredients such as semaglutide, tirzepatide, liraglutide, and dulaglutide.

What injuries may qualify for a lawsuit?

Reported injuries include gastroparesis (stomach paralysis), severe and persistent vomiting, intestinal obstruction or blockage (ileus), and other serious gastrointestinal conditions that required medical care. Eligibility depends on the diagnosis, the drug used, and the facts of each case.

What is gastroparesis (stomach paralysis)?

Gastroparesis is a disorder in which the stomach takes much longer than normal to empty its contents into the small intestine. It can cause nausea, vomiting, bloating, and a feeling of fullness, and severe cases may lead to malnutrition and other complications. There is no known cure, though stopping the medication may lessen symptoms in some people.

Is there a settlement yet?

No. These cases are consolidated in federal multidistrict litigation (MDL 3094) and remain ongoing. No settlement fund has been finalized, and eligibility and any recovery would depend on the facts of an individual case.

Related Guides

• Tylenol (acetaminophen) pregnancy autism / ADHD investigation
• Paraquat Parkinson's lawsuit
• Hair relaxer uterine cancer lawsuit

Important Disclosures

This page is for general informational purposes and does not constitute medical or legal advice. Do not stop taking any prescribed medication without consulting your physician. You should consult a qualified attorney about your individual situation. OpenClassActions.com is not a law firm and is not a claims administrator, and this page does not create an attorney-client relationship.

Free settlement alerts

Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.